ETV4 and ovarian carcinoma: PEA3 overexpression has also been observed in cancers of other organs, including the ovary, lung and gastrointestinal tract [41]–[47], and associations between decreased patient survival and PEA3 overexpression in ovarian carcinoma, gastric cancer and colorectal carcinoma (CRC) have been reported [44], [46], [47].